| Board Member | Audit Committee | Compensation Committee | Corporate Governance Committee |
|---|---|---|---|
| Kip A. Frey | M | C | |
| Alan F. Holmer | M | M | |
| Nancy J. Hutson, Ph.D. | M | ||
| Richard S. Kent, M.D. | C | ||
| Kenneth B. Lee, Jr. | C | M | |
| Jonathan S. Leff | M | ||
| Christy L. Shaffer, Ph.D. |
C = Committee Chairman, M = Committee Member.
Kenneth
B. Lee, Jr. has served as a director since September 2003 and as Chairman
of the Board since February 2005. He has also served as a member of our
Compensation Committee and Chairman of our Audit Committee since 2003, and
serves as our Audit Committee Financial Expert. He previously served as
a member of the Corporate Governance Committee from February 2005 to June
2005 and as our Vice-Chairman of the Board from March 2004 to January 2005.
Mr. Lee has over 35 years of experience with technology-based companies.
Mr. Lee is currently a General Partner with Hatteras Venture Partners, LLC
(formerly, BioVista Capital, LLC), which he joined in 2003. Prior to that,
he served as President of A.M. Pappas & Associates, LLC, a venture capital
concern. He is a former Ernst & Young Partner, where he was employed
for 29 years, and was instrumental in the founding and successful development
of the Ernst & Young life science practice in the San Francisco Bay
Area. During his tenure with Ernst & Young, he cofounded the National
Conference on Biotechnology Ventures, the International Strategic Partnering
Conference and the Palo Alto Center for Strategic Transactions. Mr. Lee
received a Bachelor of Arts degree from Lenoir-Rhyne College and an M.B.A.
from the University of North Carolina at Chapel Hill. He is a director of
CV Therapeutics, Inc., OSI Pharmaceuticals, Inc. and POZEN Inc.
Kip
A. Frey has served as a director and as a member of our Audit Committee
since June 2002, and as the Chairman of our Corporate Governance Committee
since September 2002. Since 2001, he has been a Partner with Intersouth
Partners, an early-stage venture capital firm based in the southeast. Mr.
Frey is also currently an adjunct professor at Duke University, where he
has taught since 1998. He served as 2001-2002 Chairman of the Council for
Entrepreneurial Development in Research Triangle Park, N.C. Mr. Frey was
the Vice President and General Manager of Dynamic Commerce Applications
for Siebel Systems from 2000 until 2001. Between 1998 and 2000, he served
as the President and Chief Executive Officer of OpenSite Technologies, Inc.,
a software company acquired by Siebel Systems in May 2000. Mr. Frey has
been the leader and architect of three of Research Triangle Park' s most
notable entrepreneurial ventures, Ventana Communications Group, Accipiter,
Inc. and OpenSite Technologies, Inc. He is a member of the board of directors
of the Triangle Community Foundation, Durham Academy and several local civic
and charitable organizations. In 1999, Digital South Magazine named him
the Southeast's top CEO. Mr. Frey is a Phi Beta Kappa graduate of the University
of Southern California Film School and of Duke Law School.
Alan
F. Holmer has served as a director since February 2009 and as a member of
our Corporate Governance Committee and Audit Committee since March 2009.
Mr. Holmer previously served for two years on Inspire's Board and as a member
of the Corporate Governance Committee and the Compensation Committee, resigning
in February 2007 to accept an appointment in the U.S. Treasury Department.
Mr. Holmer recently completed service as Special Envoy for China and the
Strategic Economic Dialogue, a position to which he was appointed by Secretary
of the Treasury, Henry M. Paulson, Jr. He previously served as President
and Chief Executive officer of the Pharmaceutical Research and Manufacturers
of America (PhRMA), where for nearly ten years he led the organization that
represents the interests of leading pharmaceutical and biotechnology companies.
In addition to his pharmaceutical industry experience, Mr. Holmer has significant
expertise in handling legal, international trade and governmental issues,
having held various positions within the office of the U.S. Trade Representative,
the Commerce Department and the White House, including serving as Deputy
U.S. Trade Representative with rank of Ambassador. Mr. Holmer also served
as a partner at the international law firm, Sidley & Austin (now Sidley
Austin LLP), and as an associate at Steptoe & Johnson LLP. Mr. Holmer
has been involved in many community service organizations, included currently
serving as the Chairman of the Board of the Metropolitan Washington, D.C.
Chapter of the Cystic Fibrosis Foundation and the Chair of the chapter's
Volunteer Leadership Initiative. He also served as Co-Chairman of the President's
Advisory Council on HIV/AIDS. Mr. Holmer received an A.B. degree from Princeton
University and a J.D. from Georgetown University Law Center.
Nancy
J. Hutson, Ph.D. has served as a director and as a member of our Compensation
Committee since October 2006. She has also served as the Chairperson of
our Development Committee since March 2009. She previously served as a member
of our Audit Committee from June 2008 until March 2009. Dr. Hutson retired
from Pfizer, Inc., where she spent 25 years in various research and leadership
positions, most recently serving as Senior Vice President, Global Research
and Development and Director of Pfizer's largest pharmaceutical R&D
site, known as Groton New London Laboratories. In January 2006, she was
awarded a Women of Innovation award by the Connecticut Technology Council
for research innovation and leadership for her work at Pfizer's Groton New
London Laboratories, where she led 4,500 scientists and managed a budget
in excess of $1 billion. While at Pfizer, Dr. Hutson was an active member
of numerous committees, serving as Chair of the Groton New London Laboratories
Leadership Team and the Exploratory Development Strategy Team, and as a
member of the Worldwide Development Operations Group, Senior Leadership
Team and the Pharmaceuticals Steering Committee, among others. She was also
a sponsor of the Network of Executive Women where she served as a mentor
for senior women at Pfizer Global Research & Development. Dr. Hutson
has served on various community boards, including the African Medical and
Research Foundation, the University of Connecticut Health Science Center,
and the Connecticut Business & Industry Association. She has authored
or co-authored more than 45 academic research papers and abstracts. Dr.
Hutson received her B.A. in General Biology from Illinois Wesleyan University
and her Ph.D. in Physiology and Biochemistry from Vanderbilt University.
She completed a post-doctoral fellowship at the Diabetes and Endocrinology
Center at Vanderbilt and a postdoctoral fellowship in the Department of
Clinical Biochemistry at the University of Oxford. She is a director of
Cubist Pharmaceuticals, Inc. and Endo Pharmaceuticals Inc.
Richard
S. Kent, M.D. has served as a director and a member of our Compensation
Committee since June 2004. He has also served as the Chairman of our Compensation
Committee since September 2004 and as a member of our Development Committee
since March 2009. He previously served as a member of our Corporate Governance
Committee from June 2004 through March 2009. Dr. Kent is currently a Venture
Partner with Intersouth Partners, an early-stage venture capital firm based
in the southeast. From 2002 until April 2008, Dr. Kent served as the President
and Chief Executive Officer of Serenex, Inc. until its sale to Pfizer, and
served as President and Chief Executive Officer of Ardent Pharmaceuticals,
Inc. from 2001 until joining Serenex. In total, Dr. Kent has more than 20
years of global pharmaceutical experience, including serving as Senior Vice
President, Global Medical Affairs, and Chief Medical Officer of GlaxoSmithKline.
Prior to GlaxoSmithKline, Dr. Kent held senior positions at Glaxo Wellcome
Inc. and Burroughs Wellcome Co. At Glaxo Wellcome, he was Vice President,
U.S. Medical Affairs and Group Medical Director, from 1998 through 2001,
in addition to serving on the board of directors of Glaxo Wellcome and other
senior level operating committees responsible for directing the development
and commercialization of the company's products. Prior to such time, at
Burroughs Wellcome, he was International Director of Medical Research. Dr.
Kent has supervised dozens of Investigational New Drug Applications and
over 20 successful New Drug Applications (and equivalent submissions in
Europe and the rest of the world) in a wide range of therapeutic areas including
CNS, Antivirals, HIV, Respiratory, Gastrointestinal, Anesthesia/Critical
Care, Cardiovascular, and Oncology. Dr. Kent received his undergraduate
degree from the University of California, Berkeley and his medical degree
from the University of California, San Diego. He completed his medical training
at Harvard (Peter Bent Brigham Hospital), Stanford University Medical Center
and Duke University Medical Center, and was a member of Duke University's
medical faculty. He is board certified in both internal medicine and cardiology.
Jonathan
S. Leff, age 40, has served as a director and as a member of our Corporate
Governance Committee since July 2007. Since January 2000, he has served
as a General Partner of Warburg, Pincus & Company, which is the managing
partner of Warburg Pincus LLC, and as a Member and Managing Director of
Warburg Pincus LLC, a private equity investment firm. From January 1999
to December 1999, Mr. Leff served as a Vice President of Warburg Pincus
LLC and prior to that, he served as an Associate from July 1996 to December
1998. He is responsible for the firm' s investment activities in biotechnology,
pharmaceuticals and related industries. He received an A.B. in Government
from Harvard College and an M.B.A. from the Stanford University Graduate
School of Business. Prior to joining Warburg Pincus, he was a consultant
at Oliver, Wyman & Co. He is a director of Allos Therapeutics, Inc.,
InterMune, Inc., ZymoGenetics, Inc. and several privately-held companies.
Christy
L. Shaffer, Ph.D. has served as our Chief Executive Officer and as a director
since January 1999, as our President since June 2005, and as a member of
our Development Committee since March 2009. Dr. Shaffer joined us in 1995
as the first full-time employee and held several senior positions prior
to being appointed our Chief Executive Officer. Dr. Shaffer has over 20
years of experience in drug development within the pharmaceutical industry.
She previously served in a variety of positions in the clinical research
division of Burroughs Wellcome Co. including International Project Leader
for cardiopulmonary programs. She served as the Associate Director of pulmonary
research in the department of pulmonary/critical care medicine at Burroughs
Wellcome immediately prior to joining Inspire. Dr. Shaffer coordinated several
IND submissions and one NDA submission at Burroughs Wellcome. Dr. Shaffer
received a Ph.D. in pharmacology from the University of Tennessee and completed
two years of postdoctoral training in cardiovascular research in the Biochemistry
Department at the Chicago Medical School before her one-year postdoctoral
appointment at the University of North Carolina at Chapel Hill.